ArticleEJVES vascular forum2026
Haemorrhagic Safety Update of CLEAR-PATH: 30 Day and 12 Month Antiplatelet Therapy After Peripheral Angioplasty.
Article in EJVES vascular forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Antiplatelet therapy (APT) bleeding risks after endovascular revascularisation (EVR) in peripheral arterial disease (PAD) patients are lacking. Therefore, this Dutch, multicentre, double blind, placebo controlled randomised trial aimed to determine the haemorrhagic safety of APT within 30 days and 12 months after EVR by using data from the ongoing CLEAR-PATH trial. Methods: Symptomatic PAD patients after successful EVR were randomised to clopidogrel plus placebo or acetylsalicylic acid for 12 months. The primary endpoint was major bleeding (MB) following the TIMI (Thrombolysis in Myocardial Infarction) classification within 12 months. Secondary endpoints included MB within 12 months following ISTH (International Society on Thrombosis and Haemostasis) and BARC (Bleeding Academic Research Consortium) classification, within 30 days following all classifications, and any bleeding. Analyses were blinded for treatment since the CLEAR-PATH is ongoing. It was agreed that APT groups had MB events above 0.0% and that a difference of 3.0% within 12 months was acceptable. Results: Between August 2022 and January 2024, 470 patients were randomised. Of these, 103 patients were eligible for 12 month analysis, and 440 patients for 30 month analysis. Patients presented with chronic limb threatening ischaemia (32%) or intermittent claudication (68%). MB incidences within 12 months following TIMI, ISTH, and BARC classifications were 1.9% (95% confidence interval 0.5-6.8), 1.0%, and 2.9%, respectively. The maximum difference between APT groups was 2.8%. MB incidences within 30 days following the TIMI, BARC, and ISTH were 0.9%, 0.7%, and 1.4%, respectively. Six of seven events occurred within 30 days, three of seven events were related to vascular procedures, and one event led to cardiovascular death. Conclusion: CLEAR-PATH is building a unique, large, well phenotyped PAD cohort. The incidence of MB under APT after EVR differed per classification but was overall low; most occurred within the first 30 days and were related to vascular procedures. The APT regimens raised no haemorrhagic safety concerns; therefore, CLEAR-PATH continues per protocol. Trial registration: NL80009.041.21, www.clinicaltrialsregister.eu.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.